<p><h1>Chronic Plaque Psoriasis Therapeutics Market Research Report Unlocks Analysis on the Market Financial Status, Market Size, and Market Revenue upto 2031</h1></p><p><strong>Chronic Plaque Psoriasis Therapeutics Market Analysis and Latest Trends</strong></p>
<p><p>Chronic Plaque Psoriasis Therapeutics refers to the treatment options available for managing the symptoms and complications associated with chronic plaque psoriasis, which is the most common form of psoriasis. Psoriasis is a chronic autoimmune skin disease characterized by the rapid buildup of skin cells that results in red, inflamed patches covered with silvery scales.</p><p>The market for chronic plaque psoriasis therapeutics has been witnessing significant growth in recent years. This growth can be attributed to several factors such as the increasing prevalence of chronic plaque psoriasis, rising awareness about the available treatment options, and advancements in medical technologies.</p><p>According to market research, the global chronic plaque psoriasis therapeutics market is projected to grow at a CAGR of 5.7% during the forecast period. This growth is expected to be driven by factors such as the high demand for biologics and targeted therapies, the launch of new treatment options, and the increasing healthcare expenditure.</p><p>Moreover, the market is witnessing several trends that are expected to shape its growth in the coming years. One such trend is the growing emphasis on personalized medicine, which involves tailoring treatment options based on the individual patient's needs and characteristics. This approach aims to improve treatment efficacy and reduce adverse effects.</p><p>Additionally, the market is also witnessing the increasing adoption of combination therapies, where multiple treatment options are used simultaneously to enhance the overall treatment outcomes. Combination therapies offer improved efficacy and a better response rate compared to monotherapy.</p><p>Overall, the chronic plaque psoriasis therapeutics market is anticipated to experience steady growth in the coming years, driven by various factors including increasing prevalence, advancements in treatment options, and growing healthcare expenditure.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1665375">https://www.reliableresearchreports.com/enquiry/request-sample/1665375</a></p>
<p>&nbsp;</p>
<p><strong>Chronic Plaque Psoriasis Therapeutics Major Market Players</strong></p>
<p><p>The market for chronic plaque psoriasis therapeutics is highly competitive, with several prominent players striving to gain a larger share. Among the key companies in this market are AbbVie, Novartis International, Pfizer, Merck, Astellas Pharma, and GlaxoSmithKline.</p><p>AbbVie is a leading player in the chronic plaque psoriasis therapeutics market, with its flagship product Humira. Humira is an anti-inflammatory drug that has seen tremendous success in treating psoriasis. AbbVie's revenue from Humira reached $19.6 billion in 2020, making it one of the highest-grossing drugs globally. However, as Humira is facing patent expirations in various markets, AbbVie is investing in research and development to bring new therapies and maintain its market leadership.</p><p>Novartis International is another key player in the chronic plaque psoriasis therapeutics market. The company offers Cosentyx, a breakthrough biologic drug that targets interleukin-17A, a key cytokine involved in psoriasis. Novartis reported sales of $4.8 billion from Cosentyx in 2020, reflecting its growing market share. With ongoing clinical trials for new indications and formulations, Novartis aims to solidify its position in the psoriasis market.</p><p>Pfizer is known for its medication Xeljanz, which inhibits Janus kinases involved in the immune response. Xeljanz has shown effectiveness in treating moderate-to-severe cases of chronic plaque psoriasis. Pfizer's 2020 sales from Xeljanz reached $2.5 billion, illustrating its market success. The company is expected to focus on expanding its psoriasis portfolio with additional therapies to meet evolving patient needs.</p><p>Merck, while primarily known for its vaccines and pharmaceuticals, also operates in the psoriasis therapeutics market. The company offers Ilumya, an interleukin-23 inhibitor. Although specific revenue figures for Ilumya are not available, Merck's strong position in the pharmaceutical industry indicates its ability to compete in the psoriasis market.</p><p>Astellas Pharma and GlaxoSmithKline are also significant players in the chronic plaque psoriasis therapeutics market. Astellas Pharma offers guselkumab, a biologic therapy that targets interleukin-23, while GlaxoSmithKline provides Tremfya, another interleukin-23 inhibitor. Both companies have reported strong performances and steady growth in the psoriasis market, but specific sales figures for these products are not readily available.</p><p>The chronic plaque psoriasis therapeutics market is projected to grow steadily due to increasing prevalence of the disease and the launch of innovative treatments. The market is expected to reach a value of approximately $15 billion by 2025. As new players continue to enter the market and existing ones invest in research and development, competition is expected to intensify, driving further advancements in psoriasis treatment options.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Chronic Plaque Psoriasis Therapeutics Manufacturers?</strong></p>
<p><p>The Chronic Plaque Psoriasis Therapeutics market is witnessing significant growth trends and is expected to continue expanding in the future. This growth is primarily driven by the increasing prevalence of psoriasis, rising awareness about available treatment options, and advancements in therapeutics. The market is characterized by the presence of various pharmaceutical companies working on the development of novel drugs and biologics for psoriasis treatment. Additionally, the introduction of targeted therapies and personalized medicine is expected to further propel market growth. The future outlook of the Chronic Plaque Psoriasis Therapeutics market is promising, with a strong emphasis on research and development to cater to unmet patient needs and improve treatment outcomes.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1665375">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1665375</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Chronic Plaque Psoriasis Therapeutics Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Clinical</li><li>Non-Clinical</li><li>Inactive</li></ul></p>
<p><p>The Chronic Plaque Psoriasis Therapeutics Market includes different types of markets with distinct characteristics. The Clinical market refers to the active segment where pharmaceutical companies develop and commercialize drugs for treating chronic plaque psoriasis. The Non-Clinical market comprises research activities, such as preclinical studies and drug discovery, performed by academic institutions and research organizations. The Inactive market represents the segment where previously approved drugs are no longer marketed due to patent expirations or other reasons, but may still have potential if re-introduced or repurposed.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1665375">https://www.reliableresearchreports.com/purchase/1665375</a></p>
<p>&nbsp;</p>
<p><strong>The Chronic Plaque Psoriasis Therapeutics Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospitals</li><li>Ambulatory Surgical Centers</li><li>Others</li></ul></p>
<p><p>The chronic plaque psoriasis therapeutics market is mainly used in hospitals, ambulatory surgical centers, and other healthcare facilities. Hospitals are the primary providers of medical care and treatments for chronic plaque psoriasis patients. Ambulatory surgical centers also offer specialized treatments and procedures for such patients. The "others" category includes various healthcare facilities like dermatology clinics, specialty centers, and physician offices that provide treatments for chronic plaque psoriasis. All these settings serve as crucial application areas for the chronic plaque psoriasis therapeutics market.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Chronic Plaque Psoriasis Therapeutics Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The chronic plaque psoriasis therapeutics market is expected to exhibit significant growth across various regions, namely North America (NA), Asia Pacific (APAC), Europe, the United States of America (USA), and China. Among these regions, North America is projected to dominate the market with the largest market share percentage valuation. The region's dominance can be attributed to factors such as a high prevalence of chronic plaque psoriasis, well-established healthcare infrastructure, and the presence of key market players. Europe and the United States are expected to follow closely in terms of market share, while APAC and China are anticipated to witness rapid growth due to increasing awareness about the condition and the rising number of patients seeking treatment options.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1665375">https://www.reliableresearchreports.com/purchase/1665375</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1665375">https://www.reliableresearchreports.com/enquiry/request-sample/1665375</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>